vs
Side-by-side financial comparison of FULTON FINANCIAL CORP (FULT) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($339.0M vs $336.2M, roughly 1.0× FULTON FINANCIAL CORP). FULTON FINANCIAL CORP runs the higher net margin — 28.2% vs 13.2%, a 15.0% gap on every dollar of revenue. On growth, FULTON FINANCIAL CORP posted the faster year-over-year revenue change (4.2% vs -2.7%). Over the past eight quarters, HAEMONETICS CORP's revenue compounded faster (0.4% CAGR vs 0.2%).
Fulton Financial Corporation is an American regional financial services holding company, headquartered in Lancaster, Pennsylvania.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
FULT vs HAE — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $336.2M | $339.0M |
| Net Profit | $94.8M | $44.7M |
| Gross Margin | — | 59.7% |
| Operating Margin | — | 19.9% |
| Net Margin | 28.2% | 13.2% |
| Revenue YoY | 4.2% | -2.7% |
| Net Profit YoY | 1.9% | 19.3% |
| EPS (diluted) | $0.55 | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $336.2M | — | ||
| Q4 25 | $336.0M | $339.0M | ||
| Q3 25 | $334.6M | $327.3M | ||
| Q2 25 | $324.1M | $321.4M | ||
| Q1 25 | $318.4M | $330.6M | ||
| Q4 24 | $319.6M | $348.5M | ||
| Q3 24 | $317.7M | $345.5M | ||
| Q2 24 | $334.7M | $336.2M |
| Q1 26 | $94.8M | — | ||
| Q4 25 | $99.0M | $44.7M | ||
| Q3 25 | $100.5M | $38.7M | ||
| Q2 25 | $99.2M | $34.0M | ||
| Q1 25 | $93.0M | $58.0M | ||
| Q4 24 | $68.6M | $37.5M | ||
| Q3 24 | $63.2M | $33.8M | ||
| Q2 24 | $95.0M | $38.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | 59.7% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 59.8% | ||
| Q1 25 | — | 58.4% | ||
| Q4 24 | — | 55.5% | ||
| Q3 24 | — | 54.2% | ||
| Q2 24 | — | 52.0% |
| Q1 26 | — | — | ||
| Q4 25 | 35.7% | 19.9% | ||
| Q3 25 | 38.2% | 17.9% | ||
| Q2 25 | 37.8% | 16.8% | ||
| Q1 25 | 36.1% | 21.6% | ||
| Q4 24 | 27.0% | 16.9% | ||
| Q3 24 | 25.1% | 15.0% | ||
| Q2 24 | 30.8% | 11.8% |
| Q1 26 | 28.2% | — | ||
| Q4 25 | 29.5% | 13.2% | ||
| Q3 25 | 30.0% | 11.8% | ||
| Q2 25 | 30.6% | 10.6% | ||
| Q1 25 | 29.2% | 17.5% | ||
| Q4 24 | 21.5% | 10.8% | ||
| Q3 24 | 19.9% | 9.8% | ||
| Q2 24 | 28.4% | 11.4% |
| Q1 26 | $0.55 | — | ||
| Q4 25 | $0.53 | $0.95 | ||
| Q3 25 | $0.53 | $0.81 | ||
| Q2 25 | $0.53 | $0.70 | ||
| Q1 25 | $0.49 | $1.17 | ||
| Q4 24 | $0.36 | $0.74 | ||
| Q3 24 | $0.33 | $0.66 | ||
| Q2 24 | $0.52 | $0.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $363.4M |
| Total DebtLower is stronger | — | $1.2B |
| Stockholders' EquityBook value | $3.5B | $911.5M |
| Total Assets | $32.2B | $2.5B |
| Debt / EquityLower = less leverage | — | 1.34× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $363.4M | ||
| Q3 25 | — | $296.4M | ||
| Q2 25 | — | $292.9M | ||
| Q1 25 | — | $306.8M | ||
| Q4 24 | — | $320.8M | ||
| Q3 24 | — | $299.3M | ||
| Q2 24 | — | $344.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $3.5B | — | ||
| Q4 25 | $3.5B | $911.5M | ||
| Q3 25 | $3.4B | $849.2M | ||
| Q2 25 | $3.3B | $882.3M | ||
| Q1 25 | $3.3B | $820.8M | ||
| Q4 24 | $3.2B | $906.9M | ||
| Q3 24 | $3.2B | $878.9M | ||
| Q2 24 | $3.1B | $905.4M |
| Q1 26 | $32.2B | — | ||
| Q4 25 | $32.1B | $2.5B | ||
| Q3 25 | $32.0B | $2.4B | ||
| Q2 25 | $32.0B | $2.5B | ||
| Q1 25 | $32.1B | $2.5B | ||
| Q4 24 | $32.1B | $2.5B | ||
| Q3 24 | $32.2B | $2.5B | ||
| Q2 24 | $31.8B | $2.5B |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 1.39× | ||
| Q1 25 | — | 1.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $93.6M |
| Free Cash FlowOCF − Capex | — | $87.2M |
| FCF MarginFCF / Revenue | — | 25.7% |
| Capex IntensityCapex / Revenue | — | 1.9% |
| Cash ConversionOCF / Net Profit | — | 2.09× |
| TTM Free Cash FlowTrailing 4 quarters | — | $308.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $304.5M | $93.6M | ||
| Q3 25 | $116.1M | $111.3M | ||
| Q2 25 | $91.7M | $17.4M | ||
| Q1 25 | $703.0K | $116.6M | ||
| Q4 24 | $416.6M | $43.8M | ||
| Q3 24 | $-22.0M | $48.8M | ||
| Q2 24 | $157.8M | $-27.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | $87.2M | ||
| Q3 25 | — | $106.3M | ||
| Q2 25 | — | $13.6M | ||
| Q1 25 | — | $100.9M | ||
| Q4 24 | — | $35.2M | ||
| Q3 24 | — | $39.4M | ||
| Q2 24 | — | $-33.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | 25.7% | ||
| Q3 25 | — | 32.5% | ||
| Q2 25 | — | 4.2% | ||
| Q1 25 | — | 30.5% | ||
| Q4 24 | — | 10.1% | ||
| Q3 24 | — | 11.4% | ||
| Q2 24 | — | -9.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.9% | ||
| Q3 25 | — | 1.5% | ||
| Q2 25 | — | 1.2% | ||
| Q1 25 | — | 4.7% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 1.7% |
| Q1 26 | — | — | ||
| Q4 25 | 3.08× | 2.09× | ||
| Q3 25 | 1.16× | 2.88× | ||
| Q2 25 | 0.92× | 0.51× | ||
| Q1 25 | 0.01× | 2.01× | ||
| Q4 24 | 6.07× | 1.17× | ||
| Q3 24 | -0.35× | 1.44× | ||
| Q2 24 | 1.66× | -0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FULT
Segment breakdown not available.
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
